Regencell Bioscience Raises $20 Million in Registered Direct Offering Led by New Institutional Investor

Regencell Bioscience ( (RGC) ) has provided an announcement.

On May 19, 2026, Regencell Bioscience Holdings Limited announced it had entered into a definitive agreement with investors for a registered direct offering of 985,222 ordinary shares at $20.30 per share, led by a $19 million commitment from a new fundamental institutional investor with additional participation from Univest Securities. The transaction, expected to close around May 20, 2026, should generate approximately $20 million in gross proceeds, bolstering the company’s capital base and potentially strengthening its financial flexibility as it advances its Traditional Chinese Medicine-based neurology pipeline and market ambitions.

Univest Securities is serving as the sole placement agent in the offering, which is being conducted under Regencell’s effective shelf registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission on March 30, 2026. By securing a substantial investment from a new institutional backer and leveraging an established capital markets framework, Regencell is signaling growing institutional interest and reinforcing its capacity to fund development and commercialization efforts in the competitive neurocognitive treatment space.

More about Regencell Bioscience

Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on researching, developing and commercializing Traditional Chinese Medicine-based therapies for neurocognitive disorders and degeneration. The Hong Kong-headquartered firm targets conditions such as Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder, aiming to establish a global position in natural, holistic treatments for neurological disorders.

Average Trading Volume: 134,537

Technical Sentiment Signal: Buy

Current Market Cap: $14.13B

For an in-depth examination of RGC stock, go to TipRanks’ Overview page.